IT is well known that whereas folic acid antagonists may induce temporary remissions in various forms of malignant disease, apparently permanent remissions can be obtained in a high proportion of patients with choriocarcinoma. Broquist (1956) and Hiatt, Goldstein and Tabor (1958) observed that patients receiving a folic acid antagonist for leukaemia showed an abnormal excretion of formiminoglutamic acid in patients with various forms of cancer before any form of therapy. It has also been reported that patients with cancer, including the leukaemias, frequently have low serum folate values (Rao et al., 1965) but others have suggested that this correlated with nutritional status (Hellman, Iannotti and Bertino, 1964) and that the serum folate was not more depressed than in comparable hospital patients with non-malignant disease (Spector, Hutter and Fedorko, 1966) .
In the present paper we report the serum folate and formiminoglutamic acid excretion of patients with trophoblastic tumours. Changes in formiminoglutamic acid (FIGLU) excretion during treatment with the folic acid antagonist methotrexate have also been studied in some of these patients.
MATERIALS AND METHODS
FIGLU excretion test.-The patients were given 15 g. of L-histidine monochloride orally, during a half hr. period, and the urine was collected for 8 hr. starting 1 hr. after commencing to take the histidine. The collecting bottle contained 10 ml. N HCI as a preservative and was stored at -20°C. until assayed.
E.stirnation ofFIGLU.-FIGLU was determined by modification of the spectrophotometric enzyme method of Chanarin and Bennett (1962) .
As some of the urine specimens contained methotrexate, it was necessary to inhibit all the folic reductase present at the end of pre-incubation. Excess methotrexate (5 ,tg.) was added to all the incubation tubes before the addition of standards and urine samples.
Serum folate.-Serum folate was estimated by the L. casei method of Waters et al. (1961) and Waters and Mollin (1963) with the following modifications. The serum was diluted 1: 50 with the ascorbate phosphate buffer before autoclaving, and the time of incubation of the inoculated tubes was increased to 40 hr.
Chorionic gonadotrophin.-Chorionic gonadotrophin (HCG) was measured in 24 hr. urine samples by the method of Wilde, Orr and Bagshawe (1967) .
Subjects and treatment re'gimes
The patients studied and the analyses performed are indicated in Table I . The treatment regimes received by patients studied with serial-estimations of FIGLU excretion are shown in Table II . . Methotrexate 5 mg. daily by continuous intra-arterial infusion for 5-7 days followed by a 7-9 days rest period.
Methotrexate 25 mg. daily by continuous intra-arterial infusion for 7 days followed by a 7 days rest period. Folinic acid (leucovorin) 6 mg. every 12 hr., intramuscularly, throughout the infusion period.
RESULTS
The results are summarised in Table III (Fig. 2) . There was significant correlation between these factors but the correlation was not close. Before treatment, serum folate was below 5 m,tg./ml. in 19 of 34 subjects studied.
The results of serial FIGLU determinations on patients undergoing treatment are shown in Fig. 3 . With treatment regime No. 1, FIGLU excretion remained high throughout the period of study (Fig. 3a) . Similarly, 2 of 3 patients who received small amounts of methotrexate alone by continuous infusion also had persistently high FIGLU excretion (Fig. 3b) . The other subject in this group showed low FIGLU excretion throughout. The patients who received folinic acid in conjunction with methotrexate ( Fig. 3c) Correlation: r = 0-52
DISCUSSION
More than half our patients with trophoblastic tumours had subnormal serum folate values before treatment. Those with extensive disease tended to have lower values and this is reflected in an inverse relationship with the patient's gonadotrophin excretion. The amount of gonadotrophin excreted provides an index of the amount of viable tumour tissue so that it may be inferred that the more extensive the disease the greater the probability that the serum folate is low. Similarly there is a tendency for low serum folate levels to be found with increasing time between the end of pregnancy and the time of diagnosis. Since the extent of disease is likely to be influenced by its duration the association is not unexpected. It is clear that the correlation between serum folate and extent of disease as judged by HCG excretion is not a close one. There was no obvious correlation between serum folate values and parity in these subjects.
The excretion of formiminoglutamic acid following a histidine load reflects the availability of folate co-enzymes and the excretion of this metabolite might there-35 fore be expected to relate to serum folate values, but in the present data such a relationship is dubious.
During treatment with methotrexate, a folic acid antagnoist, the pattern of change in FIGLU excretion seems to be largely determined by the therapeutic regime but since the 3 treatment groups were not similarly constituted with respect to the type and extent of trophoblastic disease, this is not conclusive. The group which received methotrexate by continuous intra-arterial infusion, together with intermittent injections of folinic acid (leucovorin), either had normal values for FIGLU throughout or they showed progressively falling values. In this group the folinic acid evidently permitted histidine to be metabolised by normal pathways and it is notable that although this therapeutic r6gime is generally accompanied by little toxicity and wider safety margins, it is not less efficient therapeutically against choriocarcinoma than r6gimes which cause more The excretion of FIGLU after histidine loading changed during treatment but appeared to be determined by the nature of the therapeutic r6gime. A treatment regime in which folinic acid was used in conjunction with the folic acid antagonist resulted in high FIGLU excretion falling to low values without any impairment of therapeutic efficiency.
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